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ABSTRACT
Background Craniosynostosis, the premature fusion of
one or more cranial sutures, occurs in ∼1 in 2250
births, either in isolation or as part of a syndrome.
Mutations in at least 57 genes have been associated
with craniosynostosis, but only a minority of these are
included in routine laboratory genetic testing.
Methods We used exome or whole genome
sequencing to seek a genetic cause in a cohort of 40
subjects with craniosynostosis, selected by clinical or
molecular geneticists as being high-priority cases, and in
whom prior clinically driven genetic testing had been
negative.
Results We identiﬁed likely associated mutations in 15
patients (37.5%), involving 14 different genes. All genes
were mutated in single families, except for IL11RA (two
families). We classiﬁed the other positive diagnoses as
follows: commonly mutated craniosynostosis genes with
atypical presentation (EFNB1, TWIST1); other core
craniosynostosis genes (CDC45, MSX2, ZIC1); genes for
which mutations are only rarely associated with
craniosynostosis (FBN1, HUWE1, KRAS, STAT3); and
known disease genes for which a causal relationship
with craniosynostosis is currently unknown (AHDC1,
NTRK2). In two further families, likely novel disease
genes are currently undergoing functional validation. In
5 of the 15 positive cases, the (previously unanticipated)
molecular diagnosis had immediate, actionable
consequences for either genetic or medical management
(mutations in EFNB1, FBN1, KRAS, NTRK2, STAT3).
Conclusions This substantial genetic heterogeneity,
and the multiple actionable mutations identiﬁed,
emphasises the beneﬁts of exome/whole genome
sequencing to identify causal mutations in
craniosynostosis cases for which routine clinical testing
has yielded negative results.
INTRODUCTION
Accurate molecular classiﬁcation is critical for the
clinical management, counselling and prognosis of
individuals with suspected monogenic diseases, par-
ticularly where early diagnosis and intervention
would substantially inﬂuence decision-making by
the clinician or family. Traditional phenotypically
guided genetic testing may fail to identify rarer
causes of disease as many conditions have a highly
variable clinical presentation. The use of next-
generation sequencing (NGS) technologies to inter-
rogate the exome sequence (ES) or whole genome
sequence (WGS) may circumvent some of these dif-
ﬁculties since these approaches are agnostic to the
underlying genetic cause.1–3
Craniosynostosis, a condition that affects ∼1 in
2250 births,4 5 is deﬁned as the premature fusion
of one or more of the normally patent cranial
sutures, a consequence of disruption in the coordi-
nated patterning, proliferation and differentiation
of these tissues.6 It has a highly heterogeneous and
complex aetiology with contributions from mono-
genic, chromosomal, polygenic and environmental
factors all playing a role.7 8 Craniosynostosis most
commonly occurs in isolation, but a minority of
cases are associated with additional clinical features
as part of a syndrome, probably reﬂecting the
co-option of pleiotropic signalling pathways to
pattern and maintain the suture; association with
>100 human syndromes has been reported.9 An
underlying genetic cause can be identiﬁed in ∼24%
of cases, with mutations in just six genes (in
decreasing order of frequency: FGFR2, FGFR3,
TWIST1, TCF12, ERF and EFNB1) together
accounting for over three-quarters of monogenic
diagnoses.10–19 At least 52 other genes have been
identiﬁed as recurrently mutated in craniosynosto-
sis,8 20 but these rarer targets do not tend to be
included in molecular testing panels unless indi-
cated by speciﬁc clinical features. Craniosynostosis
may also present as a low-frequency association
with intellectual disability syndromes, possibly
related to disturbed maintenance of suture
patency.8
To evaluate the utility of ES and WGS in this
context, we used these technologies to search for a
molecular diagnosis in 40 patients with craniosy-
nostosis who had previously been evaluated using
existing routine molecular testing, without a diag-
nosis being made. Cases were identiﬁed as being of
high priority for further investigation either by
craniofacial clinical geneticists or by laboratory
scientists specialising in craniofacial molecular
diagnostics. From this cohort, we identiﬁed an
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underlying molecular lesion in 15 (37.5%) families. We docu-
ment several cases where the mutation identiﬁed either did not
obviously ﬁt with the original clinical diagnosis or where identi-
ﬁcation of the causal mutation would have proved difﬁcult using
traditional methods of molecular testing. We highlight ﬁve fam-
ilies for which diagnosis has immediately impacted on clinical
management or counselling. This work illustrates the molecular
diversity of causes of craniosynostosis and the added value that
can be gained by a comprehensive diagnostic approach in difﬁ-
cult cases.
SUBJECTS AND METHODS
Ethics statement and prior clinical investigation
Written, informed consent for genetic research and publication
of clinical photographs was obtained by the referring clinicians
and their research teams. DNA was extracted from whole blood.
Genetic testing by a clinically accredited laboratory was guided
by the judgement of the referring clinician and diagnostic
laboratory but usually included dideoxy sequencing of TWIST1,
TCF12 and ERF (entire gene), FGFR2 and FGFR3 (regions
enriched for craniosynostosis-associated mutations) and
multiplex-ligation-dependent probe ampliﬁcation of TWIST1 to
exclude heterozygous deletions.7 17 18 Since chromosomal
abnormalities account for 13–15% of genetic diagnoses in cra-
niosynostosis,10 17 a karyotype or array comparative genomic
hybridisation was undertaken in the majority of cases.
Cohort description
Subjects with craniosynostosis, who had previously been investi-
gated by molecular genetic testing with normal ﬁndings, were
identiﬁed either by four clinical geneticists with specialist
expertise in craniosynostosis (n=36) or by clinical laboratory
scientists working in a specialist genetic diagnostic service
(n=20) for further investigation. Clinical geneticists were asked
to prioritise cases thought most likely to have a genetic diagnosis
(based on presence of syndromic features, multiple sutures
affected, consanguinity or positive family history, and lack of
any obvious environmental predisposition), particularly where
there were active issues with genetic counselling. Twelve of the
cases initially identiﬁed by clinical geneticists were excluded
either because further targeted genetic testing identiﬁed a
monogenic cause (one case each with mutations in ERF,18
FGFR211 and FLNA,21 and two with IL11RA mutations),22
where enrolment into the Deciphering Developmental
Disorders study 3 was considered more appropriate (n=5) or
where samples were not available for analysis (n=2). The
remaining cases (n=24), together with parental samples (where
available), were enrolled into the craniofacial research study fol-
lowing informed consent. Sequencing comprised 12 singletons,
1 parent–child duo, 10 parent–child trios and 1 trio comprising
three affected individuals. Similar criteria were used by clinical
laboratory scientists to prioritise 20 cases for ES; however, clin-
ical information tended to be more limited and availability of
sufﬁcient stored DNA sample was often a decisive factor for
case inclusion. For the laboratory samples, consent for research
investigation was sought secondarily to enable the entire exome
to be interrogated; two cases were excluded because consent
was not obtained. In 16 of the remaining 18 laboratory diagnos-
tic cases, ES was performed on the proband only; in one
instance, the exome of an affected sibling was already available,
and in another the family trio subsequently had WGS. Two
duplicate families (29 and 34) identiﬁed by both clinicians and
laboratory scientists are listed under the latter category in
table 1, which summarises the patterns of cranial suture involve-
ment and syndromic features of the ﬁnal total of 40 patients/
families analysed, with further details in online supplementary
table S1. In general, cases referred by clinical geneticists exhib-
ited higher proportions of multisuture involvement and syn-
dromic features (table 1). The signiﬁcance of differences
between two groups was calculated using Fisher’s exact test.
Exome and whole genome sequencing
Exome capture of DNA from patients was carried out using the
TruSeq v2 (Illumina), SureSelect Human All Exon Kit v4/v5
(Agilent) or SeqCap EZ Human Exome Library v2.0
(NimbleGen) following the manufacturer’s instructions. We gen-
erated a library for each sample using DNA extracted from
whole blood; usually we employed 3 μg DNA, except for
SureSelect v5 processed samples from families 8, 16 and 17
only, for which we used 200 ng DNA. ES was performed on an
Illumina HiSeq 2000 or 4000, with 75 or 100 bp paired-end
reads. WGS was performed on 5 μg DNA extracted from blood
Table 1 Cranial suture involvement in patients recruited for exome sequence/whole genome sequence
Non-syndromic Syndromic Combined
Total Mutation positive Total Mutation positive Total Mutation positive
Clinical genetic cases
Metopic 0 0 2 2 2 2
Sagittal 0 0 0 0 0 0
Unicoronal 0 0 1 0 1 0
Bicoronal 2 0 2 2 4 2
Multisuture 3 1 12 5* 15 6
Total 5 1 17 9 22 10
Molecular genetic cases
Metopic 0 0 0 0 0 0
Sagittal 0 0 2 0 2 0
Unicoronal 5 1 1 1 6 2
Bicoronal 2 0 2 1* 4 1
Multisuture 1 0 5 2 6 2
Total 8 1 10 4 18 5
*Includes likely novel disease gene, still undergoing validation.
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by Complete Genomics (a BGI Company) and analysed as previ-
ously described.23
Bioinformatic analysis
ES reads were mapped to the GRCh38 reference genome with
Bowtie 224 and removal of artefacts (unmapped sequences,
duplicate PCR products and likely pseudogene sequences) using
custom Perl scripts.18 Variants were called using SAMtools
v1.125 and Platypus v0.5.2.26 Sequence reads from WGS were
mapped to the GRCh37 reference genome and analysed as pre-
viously described.23 The pathogenicity of each variant was given
a custom deleterious score based on a six-point scale,27 calcu-
lated using output from ANNOVAR.28 Variants predicted to
affect splicing were assigned a deleterious score based on
MaxEntScan score differences,29 and the relationship of variants
present in known disease-causing genes analysed for pathogen-
icity using ClinVar.30 Variants with minor allele frequency
(MAF) >1% in dbSNP or ExAC were removed, and remaining
variants examined manually by visualisation in GBrowse (hg37/
hg38).31
In families comprising parent–child trios with a sporadic
affected individual, we evaluated variants based on all likely
modes of inheritance; de novo mutation, recessive (homozygous
and compound heterozygous) and X-linked hemizygous variants
(in males). For cases in which the parents were known to be
related, the proband was usually sequenced as a singleton and
the data interrogated for homozygous changes. For all samples,
data were analysed for variants in 57 genes recurrently mutated
in craniosynostosis8 and 1313 genes curated as being mutated in
developmental disorders.3
Variant validation
Conﬁrmation of variants was carried out by dideoxy sequencing
or restriction digest of genomic PCR ampliﬁcation products.
Primer sequences and conditions are detailed in online
supplementary table S2. Ampliﬁcation products were sequenced
using the BigDye Terminator v3.1 cycle sequencer system
(Applied Biosystems) and visualised using BioEdit Sequence
Alignment Editor (Ibis Biosciences) and Mutation Surveyor
Software (SoftGenetics).
Where a previously undescribed de novo variant was identi-
ﬁed in a singleton sample (ie, HUWE1), correct sample relation-
ships of the trio were checked by demonstrating consistent
inheritance of nine microsatellite loci (D1S2826, D3S1311,
D5S2027, D6S1610, D9S158, D10S548, D13S1265, D14S280
and D18S474), labelled with 6-FAM ﬂuorescent tags.
RESULTS
Overview of molecular ﬁndings
We used either ES (n=37) or WGS (n=3) to seek a causative
mutation in the two patient cohorts. In the cases from clinical
geneticists (n=22), interpretation was often assisted by sequen-
cing samples from unaffected parents or affected ﬁrst-degree
relatives; 23 additional samples were sequenced in this group
(see online supplementary table S1). For most cases from the
diagnostic laboratory, samples from relatives were either unavail-
able or not consented for analysis of ES/WGS (as described
above) and, with two exceptions (total of three additional
samples sequenced), these cases were analysed as singletons.
Mutations considered to be clinically signiﬁcant (for the diag-
nosis of craniosynostosis and/or another genetic disorder) were
identiﬁed in 15 of the 40 patients (37.5%), including two cases
associated with putative novel disease genes that are still under-
going validation (table 2). Signiﬁcantly more positive diagnoses
were found in syndromic (13/27) than non-syndromic (2/13)
patients (one-tailed p=0.046). The number of mutations identi-
ﬁed in patients recruited via clinical geneticists (including the
two duplicate ascertainments) was higher (11/24; 46%) com-
pared with those recruited via the diagnostic laboratory (5/18;
28%), likely a consequence of more rigorous clinical selection
and inclusion of sequencing data from a greater number of add-
itional family members in these cases; however, the difference
was not signiﬁcant (one-tailed p=0.19). A positive diagnosis
was obtained in a higher proportion of families in which mul-
tiple individuals were sequenced (6/14; 43%) than when single-
tons were sequenced (9/26; 35%), but this difference was also
not signiﬁcant. When the case solution rate was analysed in
terms of total samples sequenced, sequencing of multiple indivi-
duals in a family appeared less cost-effective (six solved using a
total of 40 ES/WGS; an efﬁciency of 0.43 per exome/genome
sequenced compared with singleton sequencing).
Table 2 summarises the 13 cases or families with mutation in
a validated disease gene. Seven of the mutations identiﬁed (in
AHDC1, EFNB1, FBN1, IL11RA, KRAS, MSX2, STAT3) were
previously reported; in two instances (CDC45 and HUWE1),
the patients contributed to the ﬁrst reported disease gene identi-
ﬁcation;2 32 and in four cases, the mutations are newly identiﬁed
and help to extend the genotype–phenotype spectrum (muta-
tions in IL11RA, NTRK2, TWIST1, ZIC1). The associated phe-
notypes are summarised in table 2, and complete details are
provided in online supplementary table S1. Aside from the
importance of a molecular diagnosis to end the diagnostic
odyssey and to enable precise genetic counselling (with appro-
priate estimation of recurrence risk and testing of at-risk family
members), in ﬁve families the diagnosis had unexpected, action-
able consequences for immediate clinical management. Details
of these latter cases are provided as brief case reports to illus-
trate the range of diagnostic and management issues encoun-
tered; more complete descriptions are provided as online
supplementary case reports.
Case reports
Family 11: FBN1 mutation
This boy (II-3 in ﬁgure 1A) was initially diagnosed with
Shprintzen-Goldberg syndrome based on the combination of
sagittal synostosis, blue sclerae, micrognathia, ligamentous
laxity, bilateral recurrent inguinal herniae, tall stature and mildly
abnormal aortic contour on echocardiography. However,
sequencing of SKI, in addition to TGFBR1 and TGFBR2, did
not reveal any mutations.40
ES was performed on the proband only. Concomitantly, the
referring clinician reported that the patient, now aged 8 years,
had presented with subluxed lenses; together with the aortic
ﬁndings, this suggested possible Marfan syndrome (MFS).
Scrutiny of the ES data revealed two rare heterozygous variants
in the FBN1 (Fibrillin 1) gene, c.2615A>G (p.Lys872Arg) and
c.8226+5G>A. Dideoxy-sequencing of parental samples
showed that whereas the p.Lys872Arg substitution had been
inherited from the unaffected father (not shown), the c.8226
+5G>A variant had arisen de novo (ﬁgure 1A). The c.8226
+5G>A variant, which was reconﬁrmed in a diagnostic labora-
tory, has been identiﬁed previously in a patient with a progeroid
variant of MFS;35 a different mutation of the same splice site
(c.8226+1G>A) was shown to cause skipping of the upstream
exon, introducing a frameshift and premature stop codon.41
Conﬁrmation of the molecular diagnosis of MFS has triggered
a programme of lifelong monitoring owing to the association
with progressive aortic dilatation; aged 10 years, mild aortic
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Table 2 Summary details of patients with a positive genetic diagnosis
Family Sex GENE Mutation Inheritance Ref CRS Clinical features†
3 F CDC45 c.[226A>C];[469C>T] p.[N76H];[R157C] Compound heterozygous 32 BC Short stature, thin eyebrows, anteriorly placed anus
4 M IL11RA c.[886C>T];[886C>T] p.[R296W];[R296W] Homozygous 22 P Exorbitism, intellectual disability, atopy. ?Crouzon syndrome
7 F Novel‡ Homozygous P Mid-face hypoplasia, corneal ulceration, scoliosis, severe respiratory tract infections/
bronchiectasis, mild–moderate developmental delay
9 M IL11RA c.[98dupC];[98dupC] p.[G34fs*39];[G34fs*39] Homozygous – S, BC Crouzonoid facies, mild developmental delay, dental anomalies, patent ductus arteriosus, atrial
septal defect, umbilical hernia
1o M MSX2 c.443C>T p.P148L Heterozygous (from affected
mother)
33 34 BC Mild learning difficulties, short, broad thumbs, 5th finger clinodactyly, thick hair, squint and
hydrocoele
11 M FBN1 c.8226+5G>A Splice De novo 35 S, M Exorbitism, ligamentous laxity, recurrent inguinal herniae, tall stature; lens subluxation and mild
aortic dilatation aged 8 years
14 M HUWE1 c.328C>T p.R110W De novo 2 M Facial dysmorphism, dental anomalies, pectus excavatum, scoliosis, long palms, Chiari
malformation, moderate–severe intellectual disability
16 M ZIC1 c.1101C>A p.C367* Suspected de novo§ – S, BL Microcephaly, asymmetric ventriculomegaly, possible abnormalities on MRI brain imaging
18 M TWIST1 c.350A>T p.E117V De novo – M Hypertelorism, wide anterior fontanelle, upper eyelid colobomas, pseudoproptosis, dysplastic
cupped ears, syndactyly of fingers, bilateral talipes, bilateral undescended testes, imperforate
anus, hypertrichosis
21 F KRAS c.40G>A p.V14I De novo 36 P Exorbitism, cloverleaf skull
23 F+M Novel¶ Compound heterozygous BC Bilateral superior vena cava, dilated cardiomyopathy, rudimentary right thumb, duplex kidney,
anterior anus, bilateral inguinal herniae, growth deficiency
24 F AHDC1 c.2373_2374delTG p.C791fs*57 De novo 37 BC, M Moderate developmental delay, hoarse cry
25 F EFNB1 c.325C>T p.R109C Paternal 38 RC Hypertelorism
29 M STAT3 c.1915C>T p.P639S De novo 39 P Crouzonoid appearance, mild global developmental delay; necrotising pneumonia and
bronchopleural fistula aged 3 years
37 F NTRK2 c.1330G>T p.G444* Suspected de novo§ – LC Facial asymmetry, progressive onset of aggressive outbursts, ritualised behaviours and language
delay, hyperphagic obesity, streak ovaries
†See online supplementary table S1 for detailed information.
‡Gene identity confirmed by functional testing (manuscript submitted).
§Father’s sample not available for analysis.
¶Gene identity supported by similar case found on GeneMatcher; functional testing ongoing.
CRS, sutures fused in craniosynostosis: BC, bicoronal; BL, bilambdoid; LC, left coronal; LL, left lambdoid; M, metopic; P, pansynostosis; RC, right coronal; RL, right lambdoid; S, sagittal.
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root dilatation was observed (Z score=3.02). Of note, craniosy-
nostosis is an extremely rare but previously recognised associ-
ation of MFS.42 43
Family 21: KRAS mutation
This girl presented neonatally with a cloverleaf skull appearance.
3D-CT revealed synostosis of multiple cranial sutures. There
were no additional syndromic features and cardiac examination
was normal. Raised intracranial pressure (ICP) was documented,
requiring a posterior vault expansion with springs, performed at
the age of 3 months, and insertion of a right parietooccipital
ventriculoperitoneal shunt.
WGS of the parent–child trio identiﬁed a heterozygous de
novo mutation (c.40G>A encoding p.V14I) in KRAS, which has
been reported previously in patients with Noonan syndrome.36
In the light of the exome results, an echocardiogram was per-
formed, which was normal at almost 3 years of age, but she will
continue cardiac surveillance. A coagulation screen has been
normal but recommendations have been made to repeat it prior
to any future surgery. Craniosynostosis is a rare but previously
recognised complication of Noonan syndrome, being particu-
larly associated with KRAS mutations.44
Family 25: EFNB1 mutation
The female proband (II-1 in ﬁgure 1B), the ﬁrst-born child to
healthy parents with no relevant family history, was noted to
have facial asymmetry at birth. Physical examination showed
hypertelorism and ridging over the right coronal suture. A
3D-CT scan conﬁrmed right coronal synostosis. She underwent
a fronto-orbital advancement and remodelling (FOAR) proced-
ure aged 15 months.
ES identiﬁed a heterozygous mutation (c.325C>T; p.Arg109Cys)
in the X-linked EFNB1 (ephrin-B1) gene, previously reported in a
patient with craniofrontonasal syndrome (CFNS).38 Dideoxy
sequencing of the parents showed that the clinically unaffected
father (I-1) was hemizygous for the same variant (ﬁgure 1B). CFNS
presents a paradoxical pattern of severity for an X-linked disorder,
with heterozygous females more severely affected than hemizygous
males, who can be non-penetrant.45 The result predicts that 100%
of female children of the father would be expected to exhibit CFNS
and/or craniosynostosis, and the couple have elected to enrol in a
programme of preimplantation genetic diagnosis (PIGD), selecting
only male embryos for uterine transfer.
Family 29: STAT3 mutation
This boy (II-1 in ﬁgure 1C) presented to the craniofacial unit at
2 years of age with mild mid-facial hypoplasia, a short nose
with a convex ridge, exorbitism and mild global development
delay; 3D-CT scan demonstrated fusion of all of the cranial
sutures with convexity of the closed anterior fontanelle, promin-
ent ventricles and crowded basal cisterns. At the age of 2 years
2 months, ophthalmological assessment showed bilateral papil-
loedema and invasive monitoring demonstrated signiﬁcantly
raised ICP. He underwent a posterior vault expansion with inser-
tion of springs at the age of 28 months.
ES of the proband was performed. This identiﬁed a heterozy-
gous c.1915C>T (p.Pro639Ser) mutation in the SH2 domain
Figure 1 Family pedigrees, clinical photographs/3D-CT scans and sequencing traces of families with mutations identiﬁed in FBN1 (A), EFNB1
(B) and STAT3 (C). Each panel shows the location of the mutation (red line) within the gene structure (exons in blue), family pedigree (affected
individuals are in black, black arrow depicts the proband and individuals selected for exome sequence/whole genome sequence are indicated with a
red asterisk), sequence traces of indicated individuals (red arrow indicates position of mutation) and clinical photographs (B) and 3D-CT scans (C) of
affected individuals. Note facial asymmetry associated with right unicoronal synostosis in patient with EFNB1 mutation (B); there is moderate
hypertelorism, but the grooving of the nasal tip usually observed in craniofrontonasal syndrome is absent. In the patient with the STAT3 mutation
(C), images with soft tissue windows (left and centre) show exorbitism, mid-face hypoplasia and vertex bulge; image with bone windows (right)
shows fusion of all sutures of the skull vault.
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encoded by STAT3 (signal transducer and activator of transcrip-
tion 3), which was previously reported in a case of hyper-IgE/
Jobs syndrome.40 Dideoxy-sequencing of the parents showed
that the mutation had arisen de novo (ﬁgure 1C).
Upon feedback of this ﬁnding, it transpired that the proband
had more recently presented at the age of 3 years 3 months
with an upper respiratory tract infection, progressing to severe
necrotising pneumonia with a pulmonary abscess and pneuma-
tocoele. He developed a pneumothorax and bronchopleural
ﬁstula; following two unsuccessful attempts at surgical resection,
he required a right lower lobe segmentectomy. A large secun-
dum atrial septal defect required patch closure at 5 years of age.
Further immunological assessment demonstrated a markedly ele-
vated total IgE of 3091 kU/L (normal range 0–52). He com-
menced prophylactic azithromycin and itraconazole and is
awaiting a suitably matched donor for stem cell transplantation.
Bone mineral density assessment was normal, but he takes multi-
vitamin supplements including vitamin D and is under enhanced
dental and skeletal surveillance.
Family 37: NTRK2 mutation
The female proband presented with an asymmetric face at
12 months of age and left coronal synostosis was diagnosed on
3D-CT scan; there were no syndromic features. She underwent
a FOAR procedure aged 17 months. On clinical follow-up at
the age of 2 years 8 months, she was noted to have episodes of
temper tantrums and was exhibiting speech and language delay.
By the age of 6 years, she required a school statement indicating
moderate learning difﬁculties. ES identiﬁed a heterozygous non-
sense mutation (c.1330G>T; p.Gly444*) in NTRK2, encoding
neurotrophic tyrosine receptor kinase, type 2, with a predicted
loss of the entire intracellular tyrosine kinase domain. The pro-
band’s mother did not carry the mutation and the father was
not available for analysis. Dominant mutations of NTRK2 have
been described in association with hyperphagic obesity asso-
ciated with developmental delay (OBHD), and functional
studies have pointed to haploinsufﬁciency as the likely patho-
genic mechanism of disease associated with a previously identi-
ﬁed p.Tyr722Cys substitution.46 47
The discovery of the NTRK2 mutation prompted a further
endocrinology assessment at the age of 7 years 6 months. Her
height was 135.2 cm (+2.04 SD), weight 46.2 kg (+3.19 SD)
and body mass index 25.3 kg/m2 (+3.1 SD), consistent with a
diagnosis of OBHD. She was noted to have a long-standing
history of hyperphagia. The oral glucose tolerance test was
normal; streak ovaries and uterus were evident on ultrasound
scan. Management implications have included referral to a clin-
ical psychologist and dietitian to address her eating behaviours,
and regular monitoring for secondary complications including
cardiovascular disease and diabetes.
DISCUSSION
We present, to our knowledge, the ﬁrst investigation of the
added value provided by ES or WGS in molecular genetic diag-
nosis of craniosynostosis, applied to two cohorts of patients
(total of 40) identiﬁed as high-priority cases by clinical or
laboratory geneticists following negative results from routine
molecular genetic testing. We identiﬁed 13 mutations in 12 con-
ﬁrmed disease genes that we considered to be pathogenic. Seven
of the particular DNA sequence changes found were previously
reported, whereas an additional six are currently unique to the
patients described here. The newly identiﬁed variants were con-
sidered pathogenic using evidence from population MAF data,
predictive computational data and studies of aberrant function
(either performed ourselves or published in the literature),
according to guidelines from the Association for Clinical
Genetic Science.48 In addition, we identiﬁed at least two likely
novel disease-associated genes; further studies to corroborate
these ﬁndings are ongoing, so details are not presented here.
Including these latter cases, our overall success rate in identify-
ing pathogenic mutations was 15/40 (37.5%), which is towards
the upper end of the range usually quoted in ES/WGS analysis
of other diseases with a major genetic component.1–3 We used a
mixed strategy of sequencing both singletons and multiple
family members; the latter strategy was associated with a higher
success rate per family, but the former with a 2.3-fold higher
success rate per sample sequenced. Although trio sequencing is
the favoured design in many other ES/WGS studies because
complete bioinformatic analysis of the data is more straightfor-
ward,1–3 singleton sequencing appears more cost-effective in a
diagnostic setting.
Craniosynostosis comprises a very diverse group of disorders
and its causes are correspondingly heterogeneous, with intra-
uterine fetal head constraint, reduced transduction of stretch
forces from the growing brain owing to poor intrinsic growth,
and polygenic background all likely to play substantial roles, in
addition to monogenic causes.8 Since a major motivation of this
work was to use NGS to identify novel disease genes in cranio-
synostosis, we selected cases suspected to have a genetic cause,
based on positive family history, presence of additional syn-
dromic features or multiple suture fusions, and for which clinic-
ally guided genetic testing had been normal. Although this
strategy was successful, with at least four newly recognised
disease genes for craniosynostosis being identiﬁed as part of this
study (CDC4532 and HUWE1,2 and two awaiting further cor-
roboration), the major ﬁnding presented here is that NGS is
very valuable for diagnosis of a long ‘tail’ of rare genetic asso-
ciations with craniosynostosis. All of these positive diagnoses
have made a critical difference to genetic counselling, with some
having broader management implications.
To understand why a genetic diagnosis in craniosynostosis
may elude standard molecular diagnostic testing, we categorised
each additional diagnosis in terms of the molecular genetic
framework recently presented by Twigg and Wilkie.8 These
authors identiﬁed 57 genes as recurrently mutated in craniosy-
nostosis, of which they categorised 20 as ‘core genes’ (craniosy-
nostosis present in >50% of patients with speciﬁc categories of
mutation in that gene), while mutations in the remaining 37
genes were associated with craniosynostosis in only a minority
of cases. The core genes could be further subdivided into six
with mutations each accounting for >0.5% of all craniosynosto-
sis and 14 more rarely mutated genes. Figure 2 summarises how
the 13 identiﬁed mutations are classiﬁed according to this
framework. While, not surprisingly, the number of mutations
identiﬁed, as a proportion of total genes in the category, rose
progressively as the pathogenic hierarchy was ascended, there
were multiple genes in each category. This includes two genes
(NTRK2, AHDC1), for which we are unaware of any previous
association with craniosynostosis; it is unclear whether the
co-occurrence of the mutation and sentinel phenotype is caus-
ally linked (potentially through the adverse effect of the muta-
tion on brain development)8 or simply coincidental.
In the cases found to have mutations in the ‘core’ genes, the
question arises why these were not identiﬁed by testing within the
routine diagnostic service. In the patients with EFNB1 and
TWIST1 mutations, the diagnosis was missed because analysis of
the relevant gene had not been requested by the clinician; either
because of an unusually mild presentation (EFNB1, ﬁgure 1B) or a
6 Miller KA, et al. J Med Genet 2016;0:1–9. doi:10.1136/jmedgenet-2016-104215
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severe, atypical presentation (TWIST1). Of the other core genes,
homozygous mutations in IL11RA, ﬁrst described in 2011,22 are
increasingly recognised, especially in consanguineous families
from the Indian subcontinent, and clinical diagnostic testing has
now been introduced in the UK (http://ukgtn.nhs.uk/uploads/tx_
ukgtn/CRSDA_IL11RA_GD_Sept_14.pdf). Although a speciﬁc
heterozygous mutation ofMSX2 encoding Pro148His was the ﬁrst
molecular lesion to be described in craniosynostosis in 1993,49
only two further families (both segregating p.Pro148Leu) have
subsequently been reported worldwide,33 34 and the family
described here (also with p.Pro148Leu) is the ﬁrst known in the
UK. Finally, the CDC45 patient contributed to the recent identiﬁ-
cation of mutations in this gene,32 and the patient with the ZIC1
mutation extends the currently described genotype–phenotype
correlation,50 being the ﬁrst with a mutation in exon 2 and also
the ﬁrst with involvement of the sagittal suture instead of the ori-
ginally described presentation with bilateral coronal synostosis.
As in any branch of genetic medicine, achieving a precise
molecular diagnosis has immediate implications for genetic coun-
selling, both in terms of recurrence risk and for targeted prevent-
ive measures. The common craniosynostosis syndromes all show
dominant patterns of inheritance, so that when parents are clinic-
ally unaffected, empiric recurrence risks are low (around
5%).7 51 Our cohort illustrates two scenarios where providing
the standard genetic advice would substantially underestimate
recurrence risks. In family 25 (EFNB1 mutation), the clinically
unaffected father was shown to be hemizygous for the mutation
originally identiﬁed in his daughter, indicating that the risk of
CFNS in future female children is 100%. In family 3 (CDC45
mutation), the autosomal-recessive inheritance of this disorder
raises the recurrence risk for children of the unaffected parents to
25%. Both ﬁndings have affected reproductive decision-making;
one family is seeking PIGD, whereas in the other, the option not
to have further children is being considered.
In addition to the genetic implications, in several cases (muta-
tions in the FBN1, KRAS, NTRK2 and STAT3 genes), the
molecular diagnosis has had immediate implications for clinical
management, as described in the case reports, so genetic diagno-
sis was additionally important. Mutations in each of these genes
are only infrequently associated with craniosynostosis; indeed,
the presence of the craniosynostosis may have delayed correct
diagnosis by laying a confusing trail. As a result of the molecular
diagnosis, appropriate, potentially life-saving monitoring has
been instigated. The high apparent rate of rare actionable muta-
tions identiﬁed in complex craniosynostosis without an obvious
diagnosis may reﬂect developmental pleiotropy of signalling in
the cranial sutures, with multiple pathways, co-opted from more
ancient uses in embryogenesis, implicated at different stages of
suture development.8
In summary, our ﬁndings illustrate the considerable added
value provided by ES/WGS to the precise diagnosis of patients
with craniosynostosis suspected to have a genetic cause, but
where routine testing has failed to elucidate this. As technologies
improve, a strategic question in molecular diagnostics is whether
it is preferable to extend panel tests to more genes or whether to
opt directly for ES/WGS. Aside from the most common
disease-associated mutations, for which targeted testing currently
remains cost-effective, we propose, based on the distribution of
mutations identiﬁed (ﬁgure 2), together with the substantial
burden of actionable ﬁndings (case reports), a low threshold for
implementing ES/WGS. An additional beneﬁt of this strategy is
that it may identify new disease loci,2 32 enabling improved diag-
nostic and management strategies in the future.
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